Dr. Altepeter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10903 New Hampshire Ave
Silver Spring, MD 20993Phone+1 240-402-2458
Summary
- Dr. Altepeter leads a team of physicians and scientists in the Office of New Drugs, at FDA's Center for Drug Evaluation and Research (CDER) in the Division of Gastroenterology. Her interests include Inflammatory Bowel Disease, functional GI disorders, and pediatric drug development.
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/Nemours Children's Health, WilmingtonFellowship, Pediatric Gastroenterology, 2012 - 2015
- Advocate Health Care/Advocate Children’s Hospital (Oak Lawn)Residency, Pediatrics, 2008 - 2011
- University of Illinois College of MedicineClass of 2008
Certifications & Licensure
- DC State Medical License 2015 - 2024
- DE State Medical License 2012 - 2016
- IL State Medical License 2008 - 2014
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Gastroenterology
Publications & Presentations
PubMed
- 6 citationsImmune-mediated colitis associated with ocrelizumab: A new safety risk.Tiffany Kim, Allen Brinker, David Croteau, Paul R Lee, Laura E Baldassari
Multiple Sclerosis. 2023-09-01 - 11 citationsPaediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents.Nicholas M Croft, Lissy de Ridder, Anne M Griffiths, Jeffrey S Hyams, Frank M Ruemmele
Journal of Crohn's & Colitis. 2023-03-18 - 5 citationsExpediting Drug Development for Pediatric Inflammatory Bowel Disease: A Workshop to Identify Barriers and Move Forward.Tara Altepeter, Ellen Wertheimer, Jessica J. Lee
Gastroenterology. 2019-06-21
Press Mentions
- New Bowel Disorder Treatments Needed, FDA SaysApril 17th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: